期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
Complications Following Inappropriate Intravitreal Triamcinolone Acetonide Injection
1
作者 Yukishige Nakaseko Mai Kamatani +2 位作者 Mineo Kondo Yukitaka Uji masahiko sugimoto 《Open Journal of Ophthalmology》 2012年第4期114-115,共2页
Purpose: Intravitreal Triamcinolone Acetonide (IVTA) is a useful treatment option for various intraocular diseases such as Macular Edema (ME). The treatment can cause several complications, including transient elevati... Purpose: Intravitreal Triamcinolone Acetonide (IVTA) is a useful treatment option for various intraocular diseases such as Macular Edema (ME). The treatment can cause several complications, including transient elevation of intraocular pressure and cataract formation. Here, we describe an atypical complication of IVTA. Case: A 60-year-old Japanese man presented with ME associated with central retinal vein occlusion. We performed intravitreal injection of 4 mg of TA. However, the drug spread behind the posterior lens capsule and also flowed into the anterior chamber. Although the amount of TA particles behind the lens capsule decreased over time, these particles persisted for more than 2 months. Conclusion: Although IVTA is an easy and effective treatment for ME, TA is harmful when injected into inappropriate regions of the eye. Accurate IVTA injection is important for effective treatment. 展开更多
关键词 TRIAMCINOLONE ACETONIDE INTRAVITREAL INJECTION
下载PDF
玻璃体切割术结束时玻璃体腔内注射曲安奈德治疗增殖性糖尿病视网膜病变致玻璃体积血的疗效观察 被引量:1
2
作者 Yoshihiro Takamura masahiko Shimura +8 位作者 Takashi Katome Hideaki Someya masahiko sugimoto Takao Hirano Taiji Sakamoto Makoto Gozawa Takehiro Matsumura Masaru Inatani 刘雯(译) 《英国医学杂志中文版》 2019年第3期182-182,共1页
目的研究玻璃体切割术(vitrectomy,VIT)联合玻璃体腔内注射曲安奈德(intravitrealinjection of triamcinolone acetonide, IVTA)育旨否预防增殖性糖尿病视网膜病变致玻璃体积血患者术后炎症反应的发生。方法这项前瞻性、多中心、随机研... 目的研究玻璃体切割术(vitrectomy,VIT)联合玻璃体腔内注射曲安奈德(intravitrealinjection of triamcinolone acetonide, IVTA)育旨否预防增殖性糖尿病视网膜病变致玻璃体积血患者术后炎症反应的发生。方法这项前瞻性、多中心、随机研究在日本的7个中心纳入了在增殖性糖尿病视网膜病变后发生玻璃体积血的患者。患者在手术结束时玻璃腔内注射(IVTA+VIT组)或者不注射(VIT组)曲安奈德。在术前及术后3天,1周.1、3、6个月时,分别检测2组患者的前房闪辉强度、视网膜中央厚度、最佳矫正视力和眼压,并进行比较。结果 VIT组和IVTA+VIT组分别有40例和41例患者完成了6个月的随访。术后3天(P=0.033)、1 周(P=0.019)和 1 个月(P=0.037)时,VIT组的前房闪辉强度明显高于IVTA+VIT组。在观察期间视网膜中央厚度、最佳矫正视力和眼压在两组间都没有统计学差异。在术后3天伴有黄斑水肿、视网膜中央厚度>350 的患考中,IVTA+VIT组的视网膜中央厚度在术后1个月时明显低于VIT组(P=0.041)。结论玻璃体腔内注射曲安奈德联合玻璃体切割术和白内障摘除术有助于抑制增殖性糖尿病视网膜病变导致玻璃体积血患者术后的炎症反应。曲安奈德抑制糖尿病患者黄斑水肿的作用可能局限于术后早期。 展开更多
关键词 增殖性糖尿病视网膜病变 玻璃体腔内注射 玻璃体切割术 玻璃体积血 曲安奈德 疗效观察 视网膜中央 术后炎症反应
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部